Abstract:Objectives: Non-melanoma skin cancers are the most frequently occurring type of cancer worldwide. They can be effectively treated using topical dermatological photodynamic therapy (PDT) employing protoporphyrin IX (PpIX) as the active photosensitising agent as long as the disease remains superficial. Novel iron chelating agents are being investigated to enhance the effectiveness and extend the applications of this treatment modality, as limiting free iron increases the accumulation of PpIX available for light activation and thus cell kill. Methods: Human lung fibroblasts (MRC-5) and epithelial squamous carcinoma (A431) cells were treated with PpIX precursors (aminolaevulinic acid [ALA] or methyl-aminolevulinate [MAL]) with or without the separate hydroxypyridinone iron chelating agent (CP94) or alternatively, the new combined iron chelator and PpIX producing agent, AP2-18. PpIX fluorescence was monitored hourly for 6 hours prior to irradiation. PDT effectiveness was then assessed the following day using the lactate dehydrogenase and neutral red assays. Results: Generally, iron chelation achieved via CP94 or AP2-18 administration significantly increased PpIX fluorescence. ALA was more effective as a PpIX-prodrug than MAL in A431 cells, corresponding with the lower PpIX accumulation observed with the latter congener in this cell type. Addition of either iron chelating agent consistently increased PpIX accumulation but did not always convey an extra beneficial effect on PpIX-PDT cell kill when using the already highly effective higher dose of ALA. However, these adjuvants were highly beneficial in the skin cancer cells when compared with MAL administration alone. AP2-18 was also at least as effective as CP94 + ALA/MAL co-administration throughout and significantly better than CP94 supplementation at increasing PpIX fluorescence in MRC5 cells as well as at lower doses where PpIX accumulation was observed to be more limited. Conclusions: PpIX fluorescence levels, as well as PDT cell kill effects on irradiation can be significantly increased by pyridinone iron chelation, either via the addition of CP94 to the administration of a PpIX precursor or alternatively via the newly synthesized combined PpIX prodrug and siderophore, AP2-18. The effect of the latter compound appears to be at least equivalent to, if not better than, the separate administration of its constituent parts, particularly when employing MAL to destroy skin cancer cells. AP2-18 therefore warrants further detailed analysis, as it may have the potential to improve dermatological PDT outcomes in applications currently requiring enhancement. Lasers Surg. Med. 50:552-565, 2018. © 2018 The Authors. Lasers in Surgery and Medicine Published by Wiley Periodicals, Inc.

Protoporphyrin IX Photobleaching of Subcellular Distributed Sites of Leukemic HL60 Cells Based on ALA-PDT in Vitro

Photodynamic Effects of 5-Aminolevulinic Acid and Its Hexylester on Several Cell Lines

Protoporphyrin IX Production and Its Photodynamic Effects on Glioma Cells, Neuroblastoma Cells and Normal Cerebellar Granule Cells in Vitro with 5-Aminolevulinic Acid and Its Hexylester

Comparison of 5-Aminolevulinic Acid and Its Hexylester Mediated Photodynamic Action on Human Hepatoma Cells.

Correlation of in vitro cell viability and cumulative singlet oxygen luminescence from protoporphyrin IX in mitochondria and plasma membrane

Improving in vitro photodynamic therapy through the development of a novel iron chelating aminolaevulinic acid prodrug

Experimental investigation of a combinational iron chelating protoporphyrin IX prodrug for fluorescence detection and photodynamic therapy

Aminolevulinic Acid (ALA) as a Prodrug in Photodynamic Therapy of Cancer

Feature Detection and Tracking in Support of GIS

Eef1a1 Binds and Enriches Protoporphyrin IX in Cancer Cells in 5-Aminolevulinic Acid Based Photodynamic Therapy

Photoirradiation after aminolevulinic acid treatment suppresses cancer cell proliferation through the HO-1/p21 pathway

Zwitterionic Stealth Peptide-Capped 5-Aminolevulinic Acid Prodrug Nanoparticles for Targeted Photodynamic Therapy

Combined use of 5-ALA-induced protoporphyrin IX and chlorin e6 for fluorescence diagnostics and photodynamic therapy of skin tumors

An experimental investigation of a novel iron chelating protoporphyrin IX prodrug for the enhancement of photodynamic therapy

Fluorescence Detection of Protoporphyrin Ix in Living Cells: A Comparative Study on Single- and Two-Photon Excitation

Effectiveness of 5-aminolevulinic Acid-mediated Photodynamic Therapy Combined With Curcumin

Cytotoxic Effect of Protoporphyrin IX to Human Leukemia U937 Cells under Ultrasonic Irradiation

Efficacy of photodynamic therapy using 5-aminolevulinic acid-induced photosensitization is enhanced in pancreatic cancer cells with acquired drug resistance

Dual pH-responsive 5-aminolevulinic acid supramolecular prodrug micelles for enhanced photodynamic ablation of cancer cells

Differential in Vitro Sensitivity of Oral Precancerous and Squamous Cell Carcinoma Cell Lines to 5-Aminolevulinic Acid-Mediated Photodynamic Therapy

Osteocalcin, prostaglandin E2 and alkaline phosphatase in gingival crevicular fluid: their relations to periodontal status.